fashion -WSS

fashion

author：knowledge 2025-09-30 18:54:19 - browse：77

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： More doctors should go into startup world

WSS

Diversify hospital leadership teams to protect BIPOC patient health

The new shift in health care is toward less care

Heat waves linked to early deliveries, preterm births in new study

UCSF medical school apologizes for unethical prisoner experiments

Addiction doctors spar with methadone clinics over legislation

Diversify hospital leadership teams to protect BIPOC patient health

entertainment

fashion

explore

Sports medicine is finally prioritizing gender equality

More doctors should go into startup world

The high cost of giving birth even with insurance

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Sports medicine is finally prioritizing gender equality

The new shift in health care is toward less care

Moonlake's readout produced a cash windfall. Risks remain

Medicare solvency divides Republicans at the presidential debate

Novavax promises a turnaround & Lilly roils the obesity market

HPV cancer vaccine study demonstrates efficacy

focus

Insmed lung disease drug hits target in key Phase 3 trial

Insmed lung disease drug hits target in key Phase 3 trial

Akili, maker of video game for ADHD, to be acquired for 34 million

Study: New antibiotic targets gonorrhea as well as last existing drug

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Excited delirium, Elijah McClain, and emergency physicians

hotspot

hotspot

explore

explore